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In the spring of 1982, congressional concern focused for the second time 
in 3 years on an infant formula that was deficient in a required nutrient. 
In 1979 infant formulas deficient in chloride (Neo-Mull-Soy and Cho-Free, 
manufactured by Syntex Laboratories, Inc. of California) had been recalled 
from the market, following reports of illness among children who consumed the 
products. Congressional hearings thereafter led to passage of the Infant 
Formula Act of 1980, which was designed to prevent future problems of 
deficiencies in these products. The regulations promulgated under this Act 
had not been finalized, however, when a second incident of infant formula 
deficiency occurred. On Mar. 3, 1982, the Food and Drug Administration (FDA) 
and Wyeth Laboratories announced the recall of an infant formula (Nursoy in 
both concentrated liquid and ready-to-eat forms) that lacked vitamin B6 
(pyridoxine). This soy-based product is available :or infants who may be 
allergic to cow's milk formulas. In the week following the Nursoy recall 
announcement, a second brand of formula, SMA, which is also produced by 
Wyeth, was recalled. Since these specialized formulas can be the sole source 
of nourishment for infants, concern has mounted about the possible health 
consequences of deficiencies. In the vitamin B6 deficiency incident, 
congressional attention focused on the delay in completing the final 
regulations for nutrient composition, product testing and recall procedures 
required under the Infant Formula Act of 1980. 
BACKGROUND 
Although breastfeeding is the feeding of choice for the human infant, 
historical records show that mothers have long sought substitutes. These 
substitutes can be advantageous if the mother is disinclined or unable 
(either physiologically or psychologically) to breastfeed; the child is 
unable to breastfeed or has special nutritional needs; or the child is 
physically separated from the biological mother. 
It was not until late in the 19th century, however, that alternative 
feeding methods started to be fairly safe and reliable. The discovery of the 
need to pasteurize (heat-treat) cow's milk and modify its composition to be 
suitable for infant feeding, and the concomitant development of sanitary 
standards and techniques for milk handling permitted safe bottle feeding. In 
the late 1800s, milk-based feedings were formulated and prescribed by 
pediatricians who had begun to study the complex problems of feeding infants. 
Modern infant formulas evolved from these earlier mixtures. 
The composition of infant formula is important since early infancy is the 
most critical period for growth and development. It is the one time in life 
that the individual relies on a single product to provide virtually all 
required nutrients. Progress from the early carbohydrate-modified cow's miik 
mixtures to formulas closer in nutrient composition to human milk became 
possible as a result of the advances in overall nutritional knowledge, modern 
clinical studies that revealed the complexities of infant needs for various 
nutrients, ant3 technological developments that enabled large-scale production 
of wholesale formulas with standard composition. When used as directed, 
these formulas provide protein; fat, carbohydrate, Vitamins, minerals and 
water at the appropriate caloric density and in a form physiologically suited 
for the infant. Formulas provide an adequate nutritional substitute for 
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human milk in the support of infant growth and development. 
Another major benefit of the development of infant formulas has been the 
evolution of special formulas for infants with special needs. Dietary 
problems can include allergy to milk protein, lactose intolerance, 
gastrointestinal disease and/or diarrhea, low birth weight, or inborn errors 
of metabolism. Formulas have evolved from carbohydrate-modified evaporated 
milk products to milk- or whey-based formulas, and most recently, to 
lactose-free and .elemental formulas -- all of which can meet special dietary 
problems. Lactose-free formulas contain either soy protein, 
proteinhydrolyzate, or meat base. Other major ingredients include corn syrup 
solids, sucrose and vegetable oils, as well as all vitamins and minerals 
known to be essential to the infant. Soy-based formulas were the first of 
the lactose-free formulas developed for infants intolerant to milk formulas 
either due to an allergy to milk protein or a temporary deficiency of the 
enzyme, lactase (which is necessary to break down the sugar, lactose). 
According to census data in 1980, there were 3.5 million children aged one 
year or younger in the United States. Recent data reported on infants at one 
week of age indicated that in 1980 about 51% received commercially prepared 
infant formulas compared to 77% receiving formulas in 1971. This change 
occurred due to a significant increase in the number of mothers who chose to 
breastfeed their infants. Data on feedings received by infants 5 to 6 months 
of age indicated that 61% were using commercially prepared formulas in 1980 
compared to 28% in 1971. The change in use in this age group primarily 
represents a shift away from formulas made with evaporated and cow's milk to 




The 1979 recall of the Neo-Mull-Soy and Cho-Free formulas was a result of 
inadequate chloride content. Chloride exists in the body almost entirely as 
the chloride ion. It is primarily located in the extracellular fluid, with a 
small amount in red blood cells. The ion is important in the regulation of 
osmo.tic pressure, Water balance, and acid-base balance. Chloride ions are . 
linked to hydrogen ions to provide the acid medium which promotes digestion 
in the stomach. Chloride is also an activator of saliva, -which begins the 
digestion of food in the mouth. 
A minimum daily requirement of chloride has not been determined. However, 
average intake of sodium chloride (salt) assures that more than adequate 
amounts are consumed under normal conditions. Most of the chloride ingested 
comes from salt used in food processing and preparation. 
Severe losses or deficiency of chloride can lead to metabolic alkalosis. 
This condition is characterized by a pH (degree of acidity or alkalinity) of 
the blood and other body fluids above the normal pH of 7.0. The rise above 
7.0 can be clue to an excess of alkalies or the withdrawal of acids or 
chlorides from the blood. Onset of the condition is commonly the result of a 
loss of acid from excessive vomiting, but also can result from a loss of 
-potassium or ingestion of excessive amounts of sodium bicarbonate. Symptoms 
and signs include apathy, irritability, delirium, dehydration and 
occas-ionally tetany (tonic spasms of muscles). Infants experience a f a i l ~ r e  
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to gain weight, loss of appetite, lethargy and constipation. Treatment 
includes correction of the primary disorder and administration of sodium or 
potassium chloride. 
Syntex Case 
Neo-Mull-Soy and Cho-Free are two brands of infant formula that have been 
produced by Syntex Laboratories for a decade. At the time of the 1979 
recall, it was estimated that these two products represented 10-12% of the 
infant formula market in the United States and that about 20,000 children 
were consuming these special products. 
In recent years the medical profession, along with consumer groups, has 
supported the position that the addition of salt in baby foods is not good 
for the health of children. In 1974 the American Academy of Pediatrics (AAP) 
recommended that the saltsin infant foods, particularly formulas, be reduced 
to lessen the risk of elevated blood pressure in children. Along with other 
companies which had modified the salt content of their infant food products, 
Syntex removed salt (sodium chloride) from Neo-Mull-Soy and Cho-Free in 1978. 
Coincidental to the removal of salt from the formulas, a decision was made to 
drop routine chloride assaying of Syntex formulas. The decreased amount of 
chloride in the formulas caused by the removal of the sodium chloride from 
the products resulted in metabolic alkalosis in some children fed either of 
the formulas as their sole source of nourishment. 
In July 1979 the manufacturer began to receive reports from doctors of 
cases of metabolic alkalosis occurring in infants who were using 
Neo-Mull-Soy. The company notified physicians across the country about the 
problem with the product. FDA was also apprised of the situation. Late in 
July, the company convened a panel of experts to review the available data on 
the reported cases. On Aug. 1, 1979, Syntex decided to recall voluntarily 
the Neo-Mull-Soy and Cho-Free formulas. Notification of the product recall 
was sent to physicians and pediatric nurses. The notification included a 
description of the symptoms of children who had suffered problems, provided 
information concerning appropriate corrective medical measures, and asked 
that all cans of the formulas be quarantined. A statement was released to 
the news media nationwide to alert mothers and other consumers to the recall. 
Under the procedures of FDA's enforcement policy, the company attempted to 
retrieve all cans of the product. First, food brokers, wholesalers, 
retailers and hospitals were notified. Then the company embarked upon a 
program to conduct checks in order to verify the effectiveness of the recall. 
The company reportedly contacted almost all of its customers through 26,000 
visits made by the company's sales force. In total, over 2 million cans of 
the formula were destroyed. In the isolated cases where cans were found on 
store shelves, it was reportedly due to the failure of store owners and 
middlemen to follow instructions to remove the formula. 
Following the incident, Syntex reformulated Neo-Mull-Soy to assure 
appropriate levels of all ingredients, including chloride. In addition, the 
company initiated a program to conduct tests for nutrient content on all 
infant formulas that they manufactured. Finally, the company has supported 
the follow-up study of all children reported to have had adverse reactions to 
~ e o - ~ u l l - s o y  and ~ h o - ~ r e e .  This follow-up is being conducted by an 
independent team of experts. 
In a related issue, a nonprofit organization asked Syntex for the formula 
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deficient in chloride to be donated to their overseas food program. Syntex 
asked FDA for permission to donate the formula. FDA refused this request on 
the grounds that formula unfit for U.S. -babies would also be unfit for human 
infants in foreign countries. - 
VITAMIN B6 
Introduction 
The 1982 recall of the Nursoy formula was a result if inadequate vitamin 
B6. Vitamin B6 is not a single substance, hut rather a collective term for 
the naturally-occurring compounds pyridoxine, pyridoxal, and pyridoxamine. 
The vitamin is essential for cellular function and the proper metabolism of 
protein and fats. Consequently, the vitamin complex is important for the 
proper function of the blood, central nervous system (CNS), and skin. The 
~ecommended' Dietary Allowance (RDA) of adults is about 2 mg. daily. Primary 
deficiency is rare in humans since most foods contain the compound. [The 
best sources are muscle and organ meats, fish, vegetables, and whole grain 
cereals.] Secondary deficiencies may result in cases of malabsorption, 
chemical inactivation by drugs, excessive losses, and increased metabolic 
activity. Experimental deficiency in man leads to clinical evidence of 
dermatitis, inflammation in the oral cavity, cheilosis (scaling of the lips 
and angular areas of the mouth), depression, confusion and abnormal 
electroencephalograms (EEG), followed by convulsiorfs. 
For infants under 6 months of age, 0.3 mg. of vitamin B6 daily is 
considered adequate. The vitamin B6 stores of the normal newborn are 
sufficient to meet requirements for a month after birth even if the diet is 
totally devoid of vitamin B6. A daily allowance of 0.6 mg. of vitamin B6 is 
recommended for the older infant (0.5 to 1 year) consuming a mixed diet. 
General experience with commercial formulas suggests that metabolic 
requirements for the vitamin are met if vitamin B6 is present in amounts of 
0.15 mg./gm of protein or 0.04 mg./100 kilocalories provided by the formula. 
In documented cases of vitamin B6 deficiency in infants, the reported cause 
was either (1) a lack of vitamin supplementation of breastfed infants of 
poorly nourished mothers, or (2) destruction of the pyridoxine content of 
infant formula during processing. For infants, dietary deprivation of 
vitamin B6 may result in epileptic-type convulsions, weight loss, abdominal 
distress, vomiting and hyperirritability. 
Nursoy Case 
The lack of vitamin B6 in the Nursoy infant formula was identified by the 
manufacturer, Wyeth Laboratories. The incident occurred when an employee 
mistakenly placed a canister of vitamin B1 (thiamin) into a container labeled 
for vitamin B6. As a result, the batch of defective formula - contained no 
vitamin B6 and too much vitamin B1. The recalled lots of formula were 
manufactured by Wyeth between Jan. 26 and Feb. 11, 1982. The lots were 
distributed nationwide and were available for sale in retail stores beginning 
the first week of February 1982. Init'ially the recall affected 265,000 
13-02. cans of the concentrated liquid and 306,000 32-02. cans of the 
ready-to-use infant formula. However, on Mar. 11, 1982, it was announced 
that an additional 567,000 cans of SMA brand formula would also need to be- ' 
recalled. (SMA is a second brand of formula produced by this company). TEis 
announcement was followed by a third recall on Mar. 12, 1982, for an 
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additional 1.8 million cans of SMA. In each case the deficiency of vitamin 
B6 in the formulas was picked up on routine nutrient analysis, a procedure 
performed by the company for all batches of the infant formula. The 
company's batch analysis, however, is performed after the formula has been 
distributed. 
In an earlier case (1952), about 2000 infants, who took another Wyeth 
formula in which the ,vitamin B6 had been destroyed inadvertently in 
processing, had experienced COnVUlSiVe seizures. Some of these infants have 
been reported to have suffered permanent brain damage, in the form of 
cerebral palsy. In the 1982 incident, no actual cases of vitamin B6 
deficiency have been reported to date from use of the Nursoy or SMA brands of 
formula.- It is not known in the present case how many infants were fed the 
defective formula, nor whether any permanent brain damage occurred in those 
infants who were not yet taking any other foods. 
Two additional recalls of nutrient-deficient products have occurred since 
the Infant Formula Act went into effect in 1980. In August 1983 Loma Linda 
Foods (Riverside, California) recalled about 274,000 cans of its Soyalac 
Powder when it was discovered that the formula had a loss of vitamin A 
activity. In September 1983 Sunrise and Rainbow (Los Angeles) recalled about 
7,000 cans and 1,000 packets of its Naturlac Infant Formula Powder when it 
was determined that the product was deficient in copper, vitamin B6, and 
thiamine -- that is, the minimum amount required for each nutrient by the Act 
was not present in the formula when it was analyzed. 
LEGISLATIVE ACTIVITIES 
Congressional interest in this issue began with reports of the link 
established between the use of certain baby formulas and the medical 
disorder, metabolic alkalosis. A hearing was held by the Subcommittee on 
Oversight and Investigations of the House Committee on Interstate and Foreign 
Commerce Nov. 1, 1979, to examine the adequacy of the existing law and 
regulations concerning the manufacture of infant formulas, and the recall 
procedures when a product is determined to be defective. Following the 
hearing, several bills were introduced to provide specific provisions for 
infant formulas in the Federal Food, Drug and Cosmetic Act (FD&C Act), as 
amended. A number of hearings were held in both the House and Senate to 
examine the various provisions of the bills. Ultimately, H.R. ,6940 became 
law on Sept. 26, 1980 (P.L. 96-359). 
The Infant Formula Act of 1980 created a new section for infant formulas 
in the FD&C Act, Sec. 412. The term "infant formulaw was defined under Sec. 
201 (a) to mean wa food which purports to be or is represented for special 
dietary use solely as a food for infants by reason of its simulation of human 
milk or its suitability as a complete or partial substitute for human milk". 
The new provisions established minimum, an8 where appropriate maximum, levels 
for nutrient requirements in formula. A formula is deemed to be a d ~ l ~ e r a t e d  
if it does not provide nutrients in accordance with levels stated in the law, 
or if it does not meet the quality control standards for processing. The 
Secretary is permitted to revise the nutrient requirements, as it becomes 
necessary. 
On an-Lnterim basis the- Act .required the manufacturer to notify the 
Secretary every 90 days of the nutrient composition of his product until the 
quality control procedures to be promulgated by the Secretary were in effect. 
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The final regulations require the manufacturer to notify the- Secretary not 
less than 90 days before the first processing of any infant formula that the 
formula provides nutrients and meets quality control requirements in 
accordance with the law. The Secretary is also to be notified of any change- 
i? the formulation or processing of a formula to be sure that the product 
complies With the provisions of the law. In the case where a manufacturer 
has any knowledge that a formula is not in compliance and presents a risk to 
human health, the manufacturer has to notify the Secretary. 
Under the permanent provisions of the Act, in situations where a recall is 
required, regulations are to be promulgated to prescribe the scope and extent 
of recalls necessary and appropriate for the degree of risk to human health 
presented by the formula subject to the recall. The Secretary is to review 
the effectiveness of the manufacturer's recall to determine whether it 
complies with the regulations. Manufacturers are required to keep records on 
the distribution of their products for use in the event of a recall. 
The law exempts from the nutrient and notification requirements any infant 
formula that is represented and labeled for use by an infant who has an 
inborn error of metabolism, a low birth weight, or who otherwise has an 
Unusual medical or dietary problem. The Secretary may, by regulation, 
establish terms and conditions for the exemption of these special infant 
formula products. 
On Mar. 11, 1982, ,the House Committee on Energy and Commerce's 
Subcommittee on Oversight and Investigations held a hearing on the rgcall of 
the Nursoy and SMA formulas. The purpose of the hearing was to determine (1) 
the circumstances surrounding the vitamin B6 deficiency in the Wyeth 
products; (2) the status of the FDA regulations concerning infant formula 
recall and quality control being promulgated as a result of the Infant 
Formula Act of 1980; and (3) the ability of FDA to carry out the monitoring 
of su'ch recalls given present budgetary constraints. 
Congressional. oversig'ht has continued in this area to monitor the 
effectiveness of the new law and its accompanying regulations in preventing 
future incidents of defective infant formulas. 
REGULATORY ACTIVITIES 
On July 26, 1979, the Center for Disease Control (CDC) first began to 
investigate reports of defective formulas when the agency was notified by 
local health authorities in Tennessee of three cases of metabolic alkalosis 
in infants. CDC notified FDA of the reported cases associated with the 
formulas on the same day. On July 31, 1979, CDC notified FDA that 26 cases 
of metabolic alkalosis associated with the SynteX products had been 
identified. By Aug. 31, 1979, there were 115 cases listed in the CDC 
registry. 
On Aug. 1, 1979, Syntex notified FDA of its plans for recall of the 
products and for public notification. Simultaneously with initiation of the 
recall, FDA inspected the firm's three manufacturing plants in an effort to 
determine the cause of the problem and to prevent future problems. 
Information obtained during the inspections revealed that two formulation 
cha-n-ges. may have substantially- reduced- the chloride content of the products: 
in March 1978 Syntex reduced the sodium content by reducing the salt (sodixm 
chloride); and in June 1978 the soy protein isolate (protein source) was 
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changed. Another contributing factor may have been a change in the water 
supply to one of the plants. Inspections also'revealed that the firm had 
By October 1979 Syntex had reformulated its Neo-Mull-Soy product and 
planned to begin marketing it. However, FDA asked Syntex to refrain from 
marketing the modified product until FDA was assured that the newly 
formulated product was safe and would be manufactured in accordance with 
accepted nutrient standards and good manufacturing practices. 
FDA's recall actions followed the established procedures at that time. 
However, misinterpretation of recall instructions within FDA caused a delay 
in monitoring the Syntex recall. In the case of a manufacturer-initiated 
recall, FDA recall procedures require the agency to confirm the health 
hazard, evaluate the adequacy of the firm's recall strategy, and classify the 
recall. The FDA's Health Hazards Evaluation Board rated the Syntex situation 
as "life-threatening, subacute," meaning that it presented Ha significant 
probability of deathn over an extended period of time. The situation was 
classified as requiring a class 2 recall, based on the opinion that "the risk 
of death was not immediate and that there would be no irreversible health 
consequencesw if chloride was restored. While FDA's Bureau of Foods intended 
its instructions to require a 10% level of recall audit to be done by the 
agency, these instructions were misinterpreted by the FDA San Francisco 
office to mean that the minimum level of audit requirement was to be 
undertaken by the manufacturer. When reports revealed that cans of the 
defective formulas were still on store shelves, the agency notified Syntex of 
the'problem, began its own effectiveness checks, and issued a memorandum to 
all FDA bureaus and District offices clarifying recall procedures. 
As a follow-up.to the incident, FDA took several actions. It contacted 
the manufacturers of all infant formula products to express concern about the 
recent incident and urged all companies to test their formulas for 
nutritional composition. FDA also conducted its own tests to determine 
whether infant formulas currently on the market contained the amounts of the 
ingredients declared on the label. The National Institute of Child Health 
and Human Development in cooperation with FDC and CDC, initiated a 5-year 
follow-up study to assess the long-term health problems associated with use 
of the two defective Syntex formulas. 
Early in 1980 FDA convened two public meetings to discuss various aspects 
of the infant formula problem. The first was held on Feb. 19-20, to discuss . 
quality assurance and quality control procedures; manufacturing, packaging 
and labeling; and clinical tests as they relate to infant formulas. The 
second proceeding on Mar. 12-13 was a public hearing concerned with the 
possible nutrient composition of infant formulas and possible revisions of 
existing regulation on infant formulas. Prior to these meetings, FDA 
contracted with the Federation of American Societies for Experimental Biology 
(FASEB) to prepare a paper on the various topics related to infant formulas 
and provide background information for the two public proceedings. 
The agency then proposed revision of Statutory authority and regulations 
on infant formulas to require manufacturers to perform certain types of tests 
and maintain both test records and results to be available to FDA upon 
request. On Mar. 18, 1980, FDA publishe'd in the Federal Register interim 
guidelines for the nutrient Composition and nutrient levels of infant 
formulas. The recommendations on standards for nutrient levels in infant 
for-mulas +made by -the Commi,ttee- OR Nutrition for the American Academy of' 
Pediatrics (AAP) in 1976 were to be followed by infant formula manufacturers 
as interim guidelines until revisions in the existing infant formula 
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regulations were completed. The AAP guidelines for the nutrient composition 
of infant formulas are based on a consensus of experts on the nutrient 
requirements of infants and the bioavailability of'nutrients from different 
sources used in infant formulas. (Bioavailability is the degree to which a 
substance becomes available to the target tissue after administration). 
During the interim, manufacturers were to notify the Secretary (of DHHS) 
every 90 days that their formulas were in compliance with the interim 
guidelines for nutrient standards. 
In accordance with the Infant Formula Act of 1980, the proposed 
regulations for infant formula quality control procedures were published in 
%he Federal Register on Dec. 30, 1980. The comment period, which was to end 
by Mar. 2, 1981, was extended to May I, 1981. The final rules, which were 
published on Apr. 20, 1982, established quality control procedures for -the 
manufacture of infant formulas to assure that formulas contain the necessary 
nutrients at the levels specified in the Act. The rules require each 
manufacturer to establish a quality control system, but permits each firm to 
adopt the system that is best suited to its needs. The final regulations 
require that an infant formula not be shipped by a manufacturer until the 
company's own laboratory results establish that certain nutrients are present 
in the product at the required levels. The previous regulations had allowed 
an infant formula product to be distributed once the processing was complete 
without any requirement for testing for nutrient composition. Prior to the 
Infant Formula Act o'f 1980, there were no regulatory standards for the 
nutrient composition of infant formulas, and formulas were regulated under 
the good manufacturing practices (GMP) regulations applicable to food 
sanitation and requirements of low-acid canned foods. Under Title 21, new 
part 106 subpart A of the c6de of Federal Regulations (21 CFR 106A) for 
infant formula quality control procedures, regulations are established for: 
the Status and applicability of the quality control procedures regulation; 
definitions; ingredients control; in-process control; finished product 
evaluation; coding; records; and new formulations. The regulations became 
effective July 201 1982. 
In December 1982, a suit was filed against FDA by several consumer groups 
who claimed that the FDA's infant formula regulations fail to carry out the 
mandate of the 1980 law. 
In January 1982, FDA proposed regulations for recall procedures to be . 
followed by infant formula manufacturers in accordance. with the Infant 
Formula Act of 1980. These regulations were designed to facilitate the 
removal of products from the market which do not provide the nutrients 
required or are otherwise adulterated or misbranded according to the 
provisions and definitions of the Act. The recall procedures contained in 
new part 7, subpart d l  of 21 CFR specify: the scope and effect, elements, 
reports, termination, revision, and compliance for a infant formula recall. 
The final regulations were published in the Federal Register on Apr. 30, 
1982, and became effective June 1, 1982, creating specific procedures for 
infant formulas. Previously infant formulas were recalled under the general 
enforcement procedures for any food product. 
On July 12, 1983, FDA proposed in the Federal Register two additional 
rules pertaining to infant formula. One proposed rule dealt with exemptions 
to the Act for specialty formulas intended for use by infants with special 
medical or dietary needs. Under this regulation, FDA proposed to establish 
the terms'a-nd conditions.under-which those infant formulas would continue to 
be exempt. The Act exempted these formulas from requirements set forth in 
the law until special rules could be promulgated for specialty formulas. 
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s proposal would also establish quality control, nutrient, and labeling 
uirements for exempt infant formulas. The second rule, published July 12, 
concerned with revising the labeling requirements for infant formula. 
The proposal would require the label to provide a declaration of nutrients 
required, expiration date, and directions for preparation and use. This 
rule, if adopted, will provide necessary information for health care 
professionals and consumers in the appropriate preparation and use of infant 
formulas. The comment period for both rules closed Sept. 12, 1983. 
On Apr. 11, 1984, FDA published in the Federal Register a proposal to 
revise the infant formula nutrient requirements of the Infant Formula Act of 
1980 to ensure that infant formula products .are adequate in meeting the 
normal infant's total nutritional requirements. The proposed rules would 
codify most of the nutrients and nutrient levels specified in the Act without 
change. It would revise the minimum levels for calc.ium and phosphorus, set 
maximum levels for iron and iodine, and establish the minimum level for 
niacin. It would also require that any added vitamin K be in the form of 
phyllogluinone, the only form of the vitamin permitted in foods. The 
proposal is based on the recommendations of the Committee on Nutrition of the 
American Academy of Pediatrics, the Codex Alimentarius Commission's standard 
for infant formulas, and other sources. 
Although the Infant Formula Act of 1980 became law and the regulations 
promulgated under the statute are in effect, implementation and 
interpretation of the law remain unclear. Changes in the knowledge of 
nutrient needs for infants may require frequent modification of nutrient 
standaras in both the law and the regulations. It is unclear at the present 
time how the law will be interpreted with regard to special formulas 
classified under the exemption provision and whether the new rules will 
prevent future incidents of quality control problems with infant formulas. 
